Thrivent Financial For Lutherans boosted its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 5.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,840 shares of the biotechnology company’s stock after buying an additional 380 shares during the period. Thrivent Financial For Lutherans’ holdings in Enanta Pharmaceuticals were worth $241,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. ClariVest Asset Management LLC raised its position in Enanta Pharmaceuticals by 0.8% in the first quarter. ClariVest Asset Management LLC now owns 13,400 shares of the biotechnology company’s stock valued at $413,000 after buying an additional 100 shares during the last quarter. Mason Street Advisors LLC raised its position in Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 212 shares during the last quarter. Nationwide Fund Advisors raised its position in Enanta Pharmaceuticals by 3.2% in the first quarter. Nationwide Fund Advisors now owns 12,310 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 385 shares during the last quarter. Comerica Bank raised its position in Enanta Pharmaceuticals by 3.8% in the first quarter. Comerica Bank now owns 15,389 shares of the biotechnology company’s stock valued at $478,000 after buying an additional 558 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. raised its position in Enanta Pharmaceuticals by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 24,500 shares of the biotechnology company’s stock valued at $755,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 67.39% of the company’s stock.
Enanta Pharmaceuticals, Inc. (NASDAQ ENTA) opened at 38.04 on Friday. The firm’s market cap is $725.92 million. Enanta Pharmaceuticals, Inc. has a one year low of $21.00 and a one year high of $38.40. The stock’s 50 day moving average is $35.84 and its 200 day moving average is $32.15.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.38) by $0.10. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The firm had revenue of $9 million during the quarter, compared to analysts’ expectations of $9.19 million. During the same period last year, the company posted ($0.09) EPS. The company’s quarterly revenue was down 30.8% compared to the same quarter last year.
Several equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. JMP Securities upgraded shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price on the stock in a report on Tuesday, July 11th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub lowered shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $30.75.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
